At a glance
ClinicalIndex Comparison RecordN/ACompleted· 240 enrolled
Drug / intervention
MiniMed 780G Systemdevice
Likely dose
MiniMed 780G Systemfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (Insulin Aspart Injection)
In Brief
A clinical study evaluating MiniMed 780G System for Type 1 Diabetes. Completed, enrolled 240 participants across 18 sites in 3 countries.
Detailed Summary
This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection) in a home setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesAustralia, Canada, United States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionJun 2024
TodayJul 2026
First PostedFeb 4, 2022
Enrollment StartMar 17, 2022
Primary CompletionJun 21, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.4 years ago
Interventions
MiniMed 780G Systemdevice
780G System used with Insulin Fiasp® (Insulin Aspart Injection)